Progress of CX3CL1 (Fractalkine) and its receptor CX3CR1 in regulating central nervous system disease
10.16571/j.cnki.1008-8199.2020.04.015
- VernacularTitle: 趋化因子CX3CL1和受体CX3CR1在中枢神经系统疾病中的进展
- Author:
Qian-qian YANG
1
;
Ji-zheng CUI
1
;
Zhi-bin ZHAO
1
;
Xiao-bao ZHANG
1
Author Information
1. Department of Anesthesiology, The Affiliated Lianyungang Hospital of Xuzhou Medical University / the First People’s Hospital of Lianyungang, Lianyungang 222000, Jiangsu, China
- Publication Type:Journal Article
- Keywords:
central nervous system diseases;
Fractalkine;
microglia
- From:
Journal of Medical Postgraduates
2020;33(4):416-421
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, researches constituted to show that the occurrence of central nervous system diseases such as Parkinson′s disease, Alzheimer′s disease and multiple sclerosis may have association with the inflammation of central nervous system. The chemokine CX3CL1 is mainly produced by neurons and acts on the central nervous system. After binding to the receptor CX3CR1, by inhibiting the calcium influx induced by NMDA in neurons, it can promote the activation of protein kinase and activate nuclear transcription factor kappa B, reduce the release of inflammatory factors, and stabilize the status of microglia, thus suppress the inflammatory response of the central nervous system and reduce neuronal death, which play a certain role in neuroprotective effect. Therefore, the interaction between CX3CL1 and CX3CR1 is expected to be a new target in the treatment of central nervous system diseases. In this paper, the structure of CX3CL1 and its receptor CX3CR1, the interaction of signal axis and their research progress on central nervous system diseases are reviewed.
